213 related articles for article (PubMed ID: 21930086)
1. Urine metabolomics for kidney cancer detection and biomarker discovery.
Ganti S; Weiss RH
Urol Oncol; 2011; 29(5):551-7. PubMed ID: 21930086
[TBL] [Abstract][Full Text] [Related]
2. Urine metabolomics analysis for kidney cancer detection and biomarker discovery.
Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH
Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263
[TBL] [Abstract][Full Text] [Related]
3. Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.
Monteiro MS; Barros AS; Pinto J; Carvalho M; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Guedes de Pinho P
Sci Rep; 2016 Nov; 6():37275. PubMed ID: 27857216
[TBL] [Abstract][Full Text] [Related]
4. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.
Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P
J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454
[TBL] [Abstract][Full Text] [Related]
5. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer.
Kim K; Taylor SL; Ganti S; Guo L; Osier MV; Weiss RH
OMICS; 2011 May; 15(5):293-303. PubMed ID: 21348635
[TBL] [Abstract][Full Text] [Related]
6. Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Solmoirago MJ; Sánchez-González JV; Vera-Donoso CD; Martínez-Sarmiento M; España F; Navarro S; Medina P
J Proteomics; 2020 Apr; 218():103723. PubMed ID: 32126320
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive urinary metabolomic approach for identifying kidney cancerr.
Kind T; Tolstikov V; Fiehn O; Weiss RH
Anal Biochem; 2007 Apr; 363(2):185-95. PubMed ID: 17316536
[TBL] [Abstract][Full Text] [Related]
8. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
9. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems.
Rodrigues D; Monteiro M; Jerónimo C; Henrique R; Belo L; Bastos ML; Guedes de Pinho P; Carvalho M
Transl Res; 2017 Feb; 180():1-11. PubMed ID: 27546593
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic role of kidney injury molecule-1 in renal cell carcinoma.
Zhang KJ; Wilson GD; Kara S; Majeske A; Zhang PL; Hafron JM
Int Urol Nephrol; 2019 Nov; 51(11):1893-1902. PubMed ID: 31385177
[TBL] [Abstract][Full Text] [Related]
11. Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations.
Morozumi K; Kawasaki Y; Maekawa M; Takasaki S; Sato T; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2022 Jan; 113(1):182-194. PubMed ID: 34710258
[TBL] [Abstract][Full Text] [Related]
12. Searching for prognostic biomarkers for small renal masses in the urinary proteome.
Di Meo A; Batruch I; Brown MD; Yang C; Finelli A; Jewett MA; Diamandis EP; Yousef GM
Int J Cancer; 2020 Apr; 146(8):2315-2325. PubMed ID: 31465112
[TBL] [Abstract][Full Text] [Related]
13. Aquaporin-1 protein levels elevated in fresh urine of renal cell carcinoma patients: potential use for screening and classification of incidental renal lesions.
Sreedharan S; Petros JA; Master VA; Ogan K; Pattaras JG; Roberts DL; Lian F; Arnold RS
Dis Markers; 2014; 2014():135649. PubMed ID: 24803718
[TBL] [Abstract][Full Text] [Related]
14. Automated Machine Learning and Explainable AI (AutoML-XAI) for Metabolomics: Improving Cancer Diagnostics.
Bifarin OO; Fernández FM
J Am Soc Mass Spectrom; 2024 Jun; 35(6):1089-1100. PubMed ID: 38690775
[TBL] [Abstract][Full Text] [Related]
15. Urinary microRNAs: Looking for a New Tool in Diagnosis, Prognosis, and Monitoring of Renal Cancer.
Oto J; Plana E; Sánchez-González JV; García-Olaverri J; Fernández-Pardo Á; España F; Martínez-Sarmiento M; Vera-Donoso CD; Navarro S; Medina P
Curr Urol Rep; 2020 Mar; 21(2):11. PubMed ID: 32166474
[TBL] [Abstract][Full Text] [Related]
16. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights.
Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY
Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study.
Morrissey JJ; Mellnick VM; Luo J; Siegel MJ; Figenshau RS; Bhayani S; Kharasch ED
JAMA Oncol; 2015 May; 1(2):204-12. PubMed ID: 26181025
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
19. Prognostic urinary miRNAs for the assessment of small renal masses.
Di Meo A; Brown MD; Finelli A; Jewett MAS; Diamandis EP; Yousef GM
Clin Biochem; 2020 Jan; 75():15-22. PubMed ID: 31672647
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]